<DOC>
	<DOCNO>NCT02573363</DOCNO>
	<brief_summary>This phase I trial study side effect best dose selinexor give together standard chemotherapy , high dose cytarabine mitoxantrone hydrochloride , treat patient acute myeloid leukemia . Selinexor may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cytarabine mitoxantrone hydrochloride , work different way stop growth cancer cell , either kill cell , stop dividing , stop spread . Giving selinexor together standard chemotherapy may better treatment patient acute myeloid leukemia .</brief_summary>
	<brief_title>Selinexor With Combination Chemotherapy Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) selinexor combine high dose cytarabine ( HiDAC ) +mitoxantrone ( mitoxantrone hydrochloride ) acute myeloid leukemia ( AML ) patient . SECONDARY OBJECTIVES : I . To determine complete remission ( CR ) rate follow induction chemotherapy regimen combination selinexor HiDAC mitoxantrone . II . To determine toxicity combination regimen induction , consolidation maintenance . III . To determine recurrence-free survival ( RFS ) overall survival rate consolidation maintenance treatment . IV . Allogeneic ( Allo ) -stem cell transplant ( SCT ) success rate . TERTIARY OBJECTIVES : I . To monitor clearance minimal residual disease ( MRD ) Wilms tumor 1 ( WT1 ) polymerase chain reaction ( PCR ) induction , consolidation , 6 12 month maintenance treatment . II . To monitor leukemia initiate cell clearance treatment characterize leukemia initiate cell disease relapse . OUTLINE : This phase I , dose-escalation study selinexor follow dose expansion study . INDUCTION CHEMOTHERAPY : Patients receive high-dose cytarabine mitoxantrone hydrochloride per standard care day 1 5 , selinexor orally ( PO ) day 2 , 4 , 9 , 11 . Induction treatment continue 56 day absence disease progression unacceptable toxicity . Patients achieve remission may undergo allogeneic stem cell transplant proceed consolidation chemotherapy . CONSOLIDATION CHEMOTHERAPY : Patients receive high-dose cytarabine per standard care day 1 , 3 , 5 , selinexor PO day 2 , 4 , 9 , 11 . Treatment repeat every 28 day 4 course absence disease progression unacceptable toxicity . MAINTENANCE CHEMOTHERAPY : Patients achieve least stable disease consolidation chemotherapy may receive selinexor PO day 1 , 8 , 15 , 22 discretion principal investigator . Courses repeat every 28 day 12 month absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day 1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Signed , write informed consent accordance federal , local , institutional guideline Patients newly diagnose relapsed/refractory AML , except acute promyelocytic leukemia ( APL ) , require intensive induction chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Creatinine clearance &gt; 30 cc/min calculate use Cockcroft Gault ( 1976 ) formula measure Total bilirubin = &lt; 2 mg/dl unless high indirect bilirubin due congenital disorder Transaminases ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] ) = &lt; 3.0 x upper limit normal ( ULN ) unless due leukemia infiltration Prothrombin time ( PT ) partial thromboplastin time ( PTT ) = &lt; 2 x ULN Willingness ability comply schedule visit , treatment plan , laboratory test study procedure It important patient understand need use birth control study ; female patient childbearing potential must agree use dual method contraception negative serum pregnancy test screening ( &lt; 3 day prior first dose ) , male patient partner childbearing potential must agree use effective contraception study period period 3 month last dose study drug ; male female patient , effective method contraception must use throughout study three month follow last dose Treatment investigational agent within two week prior first dose study ; hydroxyurea allow control AML prior treatment study AML central nervous system ( CNS ) involvement Major surgery within 2 week first dose study drug ; patient must recover effect surgery perform great 2 week previously Patient concurrent advantage active malignancy treatment Unstable cardiovascular function : Symptomatic ischemia , Uncontrolled clinically significant conduction abnormality ( i.e. , ventricular tachycardia antiarrhythmic agent exclude ; 1st degree atrioventricular [ AV ] block asymptomatic leave anterior fascicular block/right bundle branch block [ leave anterior fascicular block ( LAFB ) /right bundle branch block ( RBBB ) ] exclude ) , Congestive heart failure ( CHF ) New York Heart Association ( NYHA ) class &gt; = 3 , Myocardial infarction ( MI ) within 3 month Uncontrolled infection require parenteral antibiotic , antiviral , antifungal within one week prior first dose ; infection control concurrent antimicrobial agent acceptable , antimicrobial prophylaxis per institutional guideline acceptable Known active hepatitis B virus ( HBV ) C virus ( HCV ) infection ; know positive HCV ribonucleic acid ( RNA ) HBsAg ( HBV surface antigen ) Known human immunodeficiency virus ( HIV ) infection Any medical condition , investigator 's opinion , could compromise patient 's safety Patients unable swallow tablet patient malabsorption syndrome , disease significantly affect gastrointestinal function Seizure cerebrovascular accident ( CVA ) last year</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>